- Home
- ORIC vs MDXG Comparison
ORIC vs MDXG Comparison
Compare ORIC & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORIC | MDXG |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ORIC | MDXG |
|---|---|---|
| Price | $10.11 | $5.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 4 |
| Target Price | ★ $19.73 | $10.00 |
| AVG Volume (30 Days) | ★ 1.4M | 956.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $19.13 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $19.11 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.90 | $4.89 |
| 52 Week High | $14.93 | $8.50 |
Technical Indicators
Market Signals| Indicator | ORIC | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 45.90 | 36.51 |
| Support Level | $9.70 | $5.03 |
| Resistance Level | $10.60 | $5.29 |
| Average True Range (ATR) | 0.78 | 0.18 |
| MACD | -0.16 | 0.06 |
| Stochastic Oscillator | 16.94 | 66.27 |
Price Performance
Historical ComparisonAbout ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.